Provided by Tiger Trade Technology Pte. Ltd.

Ovid Therapeutics Inc.

2.47
+0.12505.34%
Volume:939.14K
Turnover:2.28M
Market Cap:480.68M
PE:-9.72
High:2.47
Open:2.37
Low:2.33
Close:2.34
52wk High:3.11
52wk Low:1.18
Shares:195.00M
Float Shares:163.00M
Volume Ratio:0.69
T/O Rate:0.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2535
EPS(LYR):-0.2325
ROE:-25.96%
ROA:-23.46%
PB:2.29
PE(LYR):-10.60

Loading ...

Guggenheim Initiates Ovid Therapeutics at Buy

MT Newswires Live
·
Oct 06

Guggenheim starts Ovid Therapeutics with a Buy on OV329 potential

TIPRANKS
·
Oct 06

Ovid Therapeutics Inc. : H.c. Wainwright Raises Target Price to $5 from $4

THOMSON REUTERS
·
Sep 11

U.S. Research Roundup- Adobe, Chewy, Mosaic

Reuters
·
Sep 11

Ovid Therapeutics Management Presents at Cantor Global Healthcare Conference Webcast

Reuters
·
Sep 03

Acrivon Therapeutics Names Michaela Levin Chief Business Officer

Reuters
·
Aug 31

Oppenheimer Sticks to Its Buy Rating for Ovid Therapeutics (OVID)

TIPRANKS
·
Aug 14

Wedbush Keeps Their Buy Rating on Ovid Therapeutics (OVID)

TIPRANKS
·
Aug 14

Ovid Therapeutics Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Ovid Therapeutics Releases Corporate Presentation Outlining Neural Hyperexcitability Drug Pipeline

Reuters
·
Aug 13

Ovid Therapeutics Q2 Revenue Beats Estimates

Reuters
·
Aug 13

Ovid Q2 FY26 Net Loss Widens to $15 Million; Operating Expenses Rise to $16.4 Million

Reuters
·
Aug 13

Ovid Therapeutics Q2 Revenue USD 733 Thousand VS. Ibes Estimate USD 0

THOMSON REUTERS
·
Aug 13

Ovid Therapeutics Q2 EPS USD -0.08

THOMSON REUTERS
·
Aug 13

Ovid Therapeutics Inc. Expected to Post a Loss of 11 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Ovid Therapeutics CFO Charles Ross Files Initial Beneficial Ownership Statement

Reuters
·
Jul 09

Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed

TIPRANKS
·
Jul 08

Ovid Therapeutics Names Kevin Norrett Chief Business Officer

Reuters
·
Jul 08

Ovid Therapeutics - Promotes Charles Carter to Chief Financial Officer

THOMSON REUTERS
·
Jul 08

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

THOMSON REUTERS
·
Jul 08